Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Bass

Showing results (451-460 of 475) with videos related to

Pageof 48
Sort By:
Progress in Community Health Partnerships : Research, Education, and Action|March 9, 2010
A vision for progress in community health partnershipsS Darius Tandon, Karran Phillips, Bryan C Bordeaux, et al.
Cancer|January 4, 2007
Provider roles in the recruitment of underrepresented populations to cancer clinical trialsMollie W Howerton, M Chris Gibbons, Charles R Baffi, et al.
Journal of Lipid Research|November 1, 2008
Identification of three loci affecting HDL-cholesterol levels in a screen for chemically induced recessive mutations in miceTodd Juan, Murielle M Véniant, Joan Helmering, et al.
Evidence Report/Technology Assessment (Summary)|July 2, 2005
Knowledge and access to information on recruitment of underrepresented populations to cancer clinical trialsJ G Ford, M W Howerton, S Bolen, et al.
Journal of Clinical Epidemiology|October 17, 2022
Inclusion of nonrandomized studies of interventions in systematic reviews of interventions: updated guidance from the Agency for Health Care Research and Quality Effective Health Care programIan J Saldanha, Gaelen P Adam, Lionel L Bañez, et al.
Evidence Report/Technology Assessment (Summary)|July 2, 2005
Post-myocardial infarction depressionD E Bush, R C Ziegelstein, U V Patel, et al.
Annals of Internal Medicine|March 16, 2011
Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinationsWendy L Bennett, Nisa M Maruthur, Sonal Singh, et al.
Cancer|June 14, 2012
AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 studyBrian Rini, Cezary Szczylik, Nizar M Tannir, et al.
Clinical Genitourinary Cancer|December 25, 2013
A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinomaDavid S Hong, Michael S Gordon, Wolfram E Samlowski, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 31, 2012
Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancerM M Eatock, N C Tebbutt, C L Bampton, et al.
Pageof 48

Showing results (451-460 of 475) with videos related to

Sort By:
Pageof 48
Progress in Community Health Partnerships : Research, Education, and Action|March 9, 2010
A vision for progress in community health partnershipsS Darius Tandon, Karran Phillips, Bryan C Bordeaux, et al.
Cancer|January 4, 2007
Provider roles in the recruitment of underrepresented populations to cancer clinical trialsMollie W Howerton, M Chris Gibbons, Charles R Baffi, et al.
Journal of Lipid Research|November 1, 2008
Identification of three loci affecting HDL-cholesterol levels in a screen for chemically induced recessive mutations in miceTodd Juan, Murielle M Véniant, Joan Helmering, et al.
Evidence Report/Technology Assessment (Summary)|July 2, 2005
Knowledge and access to information on recruitment of underrepresented populations to cancer clinical trialsJ G Ford, M W Howerton, S Bolen, et al.
Journal of Clinical Epidemiology|October 17, 2022
Inclusion of nonrandomized studies of interventions in systematic reviews of interventions: updated guidance from the Agency for Health Care Research and Quality Effective Health Care programIan J Saldanha, Gaelen P Adam, Lionel L Bañez, et al.
Evidence Report/Technology Assessment (Summary)|July 2, 2005
Post-myocardial infarction depressionD E Bush, R C Ziegelstein, U V Patel, et al.
Annals of Internal Medicine|March 16, 2011
Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinationsWendy L Bennett, Nisa M Maruthur, Sonal Singh, et al.
Cancer|June 14, 2012
AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 studyBrian Rini, Cezary Szczylik, Nizar M Tannir, et al.
Clinical Genitourinary Cancer|December 25, 2013
A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinomaDavid S Hong, Michael S Gordon, Wolfram E Samlowski, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 31, 2012
Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancerM M Eatock, N C Tebbutt, C L Bampton, et al.
Pageof 48